Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025Expert Review of Hematology

Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HNHiba NarvelGAGulrayz AhmedMHMehdi Hamadani

Discussion

Loading...

Member takes

Overview

Review compares reduced-intensity conditioning and myeloablative conditioning in allo-HCT for Hodgkin lymphoma, suggesting RIC improves outcomes.

Key Points

  • Reduced-intensity conditioning offers a favorable balance between efficacy and tolerability in allogeneic HCT.
  • Allogeneic HCT remains a potentially curative option for relapsed/refractory Hodgkin lymphoma patients.
  • Immune checkpoint inhibitors can enhance graft-versus-malignancy effects but may increase graft-versus-host disease risks.
  • Post-transplant cyclophosphamide allows safer use of alternative donors in transplantation without compromising outcomes.

Cite This Study

Narvel et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d182dhttps://doi.org/10.1080/17474086.2025.2545336
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Can we move beyond myeloablative conditioning (<scp>MAC</scp>)? A comparison of <scp>MAC</scp> versus reduced intensity conditioning (<scp>RIC</scp>) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using <scp>ATG</scp>‐<scp>PTCy</scp>‐<scp>CSA</scp> for <scp>GVHD</scp> prophylaxis2025 · 2 citations
  2. 2Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study2025
  3. 3Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant2025
  4. 4Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia2025
  5. 5Allogeneic HSC and regulatory T cell  (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study2025